News >

Carboxyamidotriazole Orotate Shows Promising Activity in Brain Cancers

Jason Harris
Published: Friday, Apr 27, 2018

Elena Pentsova, MD
Elena Pentsova, MD
Carboxyamidotriazole orotate (CTO) in combination with temozolomide (Temodar), with or without radiotherapy, produced positive safety and efficacy results in a phase Ib study of patients with glioblastoma (GBM) or anaplastic gliomas.

of CTO, the next lower dose level.
Omuro A, Beal K, McNeill K, et al. Multicenter phase ib trial of carboxyamidotriazole orotate and temozolomide for recurrent and newly diagnosed glioblastoma and other anaplastic gliomas [published online April 23, 2018]. J Clin Oncol. 2018 Apr 23:JCO2017769992. doi: 10.1200/JCO.2017.76.9992.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x